Artikel
Effect of depression on psoriatic arthritis activity in patients treated with treat to target strategy using psaid-12 questionnaire after 6 years follow-up
Suche in Medline nach
Autoren
-
Polina Tremaskina
- V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritis and psoriatic arthritis, Moscow
-
Tatiana V. Korotaeva
- V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritis and psoriatic arthritis, Moscow
-
Elena Loginova
- V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritis and psoriatic arthritis, Moscow
-
Lyubov Vorobyova
- V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritis and psoriatic arthritis, Moscow
-
Svetlana Glukhova
- V.A. Nasonova Research Institute of Rheumatology, medical and social problems in rheumatology, Moscow
-
Alexander Lila
- V.A. Nasonova Research Institute of Rheumatology, rheumatology, Moscow
| Veröffentlicht: | 31. August 2022 |
|---|
Gliederung
Text
Introduction: The prevalence of depression is significantly higher in patients (pts) with PsA than in the general population [1]. Psoriatic Arthritis Impact of Disease - 12 items (PsAID-12 score) has been shown to be a reliable tool for assessing the impact of disease, including depression on PsA activity and predicting long-term disease outcomes [2]. There are no data about use PSAID-12 including assessment of depression for evaluation outcomes of treat to target (T2T) strategy. The aim of this study is to assess the effect of depression on PsA pts treated according to T2T strategy using the PsAID-12 questionnaire after 6 years follow-up.
Methods: This study assessed 50 (M/F–24/26) PsA pts fulfilling CASPAR criteria. Mean age 45±12.1 yrs, median (Me) PsA duration 82 [66;97] month (mos), Me follow-up 72 [58;89] mos. At the early stage (PsA duration≤2 yrs) all pts were treated according to T2T study within 24 mos. At 6 years follow-up all pts underwent standard clinical examination (tender joint count (TJS), swollen joint count (SJC), patient global assessment disease activity (PtGA), CRP (mg/l), skin psoriasis (PsO) by BSA (%), presence of nail PsO, enthesites, dactylitis, DAPSA) and completed PsAID-12. A total PsAID score below 4 out of 10 is considered a ‘patient-acceptable state’ (PASS). Me [Q25-Q75], M±SD, Spearman’s correlation, Mann-Whitney test were performed. All p<0.05 were considered to indicate statistical significance.
Results: Mean total PsAID-12 score was 2.62±2.1. PASS was seen in 38 out of 50 pts (76%). At 6 yrs follow-up REM-DAPSA were seen at 17 (34%), LDA in 15 (30%) pts. Depression in pts was associated with TJS (r=0.35), PtGA (r=0.49), pain score reported by pts (r=0.42), CRP (r=0.34) and HAQ (r=0.4), as well as DAPSA activity status, (r=0.48), for all p<0.05. There was no correlation between depression in pts with PsA and SJC, the presence of enthesites and dactylitis, nail psoriasis and severe skin lesions (BSA>3).
Conclusion: The presence of depression in pts treated according to T2T after 6 years follow-up is significantly associated with PsA activity according to DAPSA. PsAID-12 is a reliable measure for evaluating the long-term T2T outcomes.
References
- 1.
- Mathew AJ, Chandran V. Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation. Rheumatol Ther. 2020 Jun;7(2):287-300. DOI: 10.1007/s40744-020-00207-6
- 2.
- Queiro R, Cañete JD, Montoro M, Gómez S, Cábez A; MAAPS study group. Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study. Arthritis Res Ther. 2020 Apr 15;22(1):82. DOI: 10.1186/s13075-020-02168-1
